Is Vyne Therapeutics Inc (VYNE) overvalued? · rev $501.0K
Vyne Therapeutics Inc (VYNE) is a biotechnology company listed on NASDAQ.
This page asks whether Vyne Therapeutics Inc (VYNE) looks expensive on cached numbers — not a short thesis.
Latest reported VYNE revenue for 2024-12-31 was $501.0K. Net income was -$39.8M. Revenue was up 18.2% from 2023-12-31 to 2024-12-31. VYNE currently screens at market cap $21.1M.
VYNE currently screens at market cap $21.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next VYNE 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the VYNE stock page for the full model, not this heading.
Not investment advice.